Breakthrough for neoadjuvant chemotherapy

Breast Cancer

Volumn 15, Issue 1, 2008, Pages 27-30

  Von Minckwitz, Gunter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Breast cancer; Neoadjuvant; Prediction; Primary; TAC

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; FEMALE; HUMAN;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOADJUVANT THERAPY;

EID: 43149117496     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-007-0004-1     Document Type: Conference Paper

References (10)

1. Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600-08. (Pubitemid 46606344)
2. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940-49. (Pubitemid 46638994)
3. German Arbeitsgemeinschaft gynäkologische onkologie guidelines on neoadjuvant breast cancer therapy. Available at:http://www.ago-online.org. Accessed 30 June 2007.
4. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-74. (Pubitemid 46606185)
5. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019-27. (Pubitemid 46622110)
6. von Minckwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol. 2005a;16:56-63. (Pubitemid 40124479)
7. von Minckwitz G, Blohmer JU, Raab G, et al. Comparison of docetaxel/doxorubicin/cyclophosphamide (TAC) versus vinorelbine/ capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy-first results of the phase III GEPARTRIO-Study by the German Breast Group. San Antonio breast cancer symposium. 2005b;abstract 38.
8. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676-85.
9. von Minckwitz, Blohmer J, Vogel P, et al. Comparison of neoadjuvant 6 vs. 8 cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) in patients early responding to TACx2-the GEPARTRIO Study. J Clin Oncol. 2006b;24: abstract 576.
10. von Minckwitz G, Kuemmel S, du Bois A, et al. Individualized treatment strategies according to in vivo-chemosensitivity assessed by response after 2 cycles of neoadjuvant chemotherapy. Final results of the Gepartrio study of German breast group. San Antonio breast cancer symposium. 2006c;abstract 42.